Poly(n-butylcyanoacrylate) nanoparticles for oral delivery of quercetin: Preparation, characterization, and pharmacokinetics and biodistribution studies in Wistar rats

International Journal of Nanomedicine

Volumn 10, Issue , 2015, Pages 3921-3935

  Bagad, Mayur ^a   Khan, Zaved Ahmed ^a  

^a VIT UNIVERSITY   (India)

Author keywords

Bioavailability; Biodistribution; Nanoparticles; Pharmacokinetics; Poly (n butylcyanoacrylate); Quercetin

Indexed keywords

NANOPARTICLE; POLY(N BUTYLCYANOACRYLATE)NANOPARTICLE; POLYSORBATE 80; QUERCITRIN; UNCLASSIFIED DRUG; BIOCOMPATIBLE COATED MATERIAL; DRUG CARRIER; ENBUCRILATE; POLYSORBATE; QUERCETIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG EXCRETION; DRUG HALF LIFE; DRUG IDENTIFICATION; DRUG METABOLISM; DRUG PENETRATION; DRUG STABILITY; DRUG SYNTHESIS; DRUG TRANSPORT; EMULSION; ENCAPSULATION; IN VITRO STUDY; INTESTINE FLUID; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; POLYMERIZATION; RAT; SINGLE DRUG DOSE; STOMACH JUICE; SUSTAINED DRUG RELEASE; TIME TO MAXIMUM PLASMA CONCENTRATION; TISSUE DISTRIBUTION; TRANSMISSION ELECTRON MICROSCOPY; ZETA POTENTIAL; ANIMAL; BIOAVAILABILITY; BRAIN; CHEMICAL PHENOMENA; CHEMISTRY; DRUG EFFECTS; METABOLISM; WISTAR RAT;

RATTUS; RATTUS NORVEGICUS;

ANIMALS; BIOLOGICAL AVAILABILITY; BRAIN; CHEMICAL PHENOMENA; COATED MATERIALS, BIOCOMPATIBLE; DRUG CARRIERS; ENBUCRILATE; MALE; MICROSCOPY, ELECTRON, TRANSMISSION; NANOPARTICLES; PARTICLE SIZE; POLYSORBATES; QUERCETIN; RATS; RATS, WISTAR; TISSUE DISTRIBUTION;

EID: 84933525096     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S80706     Document Type: Article

References (51)

1. Nijveldt RJ, Nood E, Van Hoorn DEC, Boelens PG, Van Norren K, Van Leeuwen PA. Flavonoids: a review of probable mechanisms of action and potential applications. Am J Clin Nutr. 2001;74(4):418–425.
2. Erlund I. Review of the favonoids quercetin, hesperetin, and naringenin. Dietary sources, bioactivities, bioavailability, and epidemiology. Nutr Res. 2004;24(10):851–874.
3. Kim GN, Jang HD. Protective mechanism of quercetin and rutin using glutathione metabolism on H2O2-induced oxidative stress in HepG2 cells. Ann N Y Acad Sci. 2009;1171:530–537.
4. Formica JV, Regelson W. Review of the biology of quercetin and related biofavonoid. Food Chem Toxicol. 1995;33(12):1061–1080.
5. Priprem A, Watanatorn J, Sutthiparinyanont S, Phachonpai W, Muchimapura S. Anxiety and cognitive effects of quercetin liposomes in rats. Nanomedicine. 2008;4(1):70–78.
6. Huebbe P, Wagner AE, Boesch-Saadatmandi C, Sellmer F, Wolffram S, Rimbach G. Effect of dietary quercetin on brain quercetin levels and the expression of antioxidant and Alzheimer’s disease relevant genes in mice. Pharmacol Res. 2010;61(3):242–246.
7. Kumari A, Yadav SK, Pakade YB, Singh B, Yadav SC. Development of biodegradable nanoparticles for delivery of quercetin. Colloids Surf B Biointerfaces. 2010;80(2):184–192.
8. Dhawan S, Kapil R, Singh B. Formulation development and systematic optimization of solid lipid nanoparticles of quercetin for improved brain delivery. J Pharm Pharmacol. 2011;63(3):342–351.
9. Hariharan S, Bhardwaj V, Bala I, Sitterberg J, Bakowsky U, Ravi Kumar MNV. Design of estradiol loaded PLGA nanoparticulate formulations: a potential oral delivery system for hormone therapy. Pharm Res. 2006;23(1):184–195.
10. LI SD, Huang L. Pharmacokinetics and biodistribution of nanoparticles. Mol Pharm. 2008;5(4):496–504.
11. Date AA, Nagarsenker MS, Patere S, et al. Lecithin based novel cationic nanocarriers (LeciPlex) II: improving therapeutic efficacy of quercetin on oral administration. Mol Pharm. 2011;8(3):716–726.
12. Zhang Y, Yang Y, Tang K, Hu X, Zou G. Physicochemical characterization and antioxidant activity of quercetin-loaded chitosan nanoparticles. J Appl Polym Sci. 2008;107(2):891–897.
13. Gang W, Jie WJ, Ping ZL, et al. Liposomal quercetin: evaluating drug delivery in vitro and biodistribution in vivo. Expert Opin Drug Deliv. 2012;9(6):599–613.
14. Pool H, Quintanar D, Figueroa JD, et al. Antioxidant effects of quercetin and catechin encapsulated into PLGA nanoparticles. J Nanomat. 2012: Article ID 145380: 1–12.
15. Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev. 2001;47(1):65–81.
16. Yordanov G. Poly(alkyl cyanoacrylate) nanoparticles as drug carriers: 33 years later. Bulg J Chem. 2012;1:61–73.
17. Sun M, Gao Y, Guo C, et al. Enhancement of transport of curcumin to brain in mice by poly(n-butylcyanoacrylate) nanoparticles. J Nanopart Res. 2010;12:3111–3122.
18. Zhao L, Liu A, Sun M, et al. Enhancement of oral bioavailability of puer-arin by polybutylcyanoacrylate nanoparticles. J Nanomater. 2011:1–8.
19. Wilson B, Samanta MK, Santhi K, Sampath Kumar KP, Paramakrishnan N, Suresh B. Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of Rivastigmine into the brain to treat Alzheimer’s disease. Brain Res. 2008;1200:159–168.
20. Gulyaev AE, Gelperina SE, Skidan IN, Antropov AS, Kivman GY, Kreuter J. Significant transport of doxorubicin into the brain with polysor-bate 80-coated nanoparticles. Pharm Res. 1999;16(10):1564–1569.
21. Yordanov G. Influence of the preparation method on the physi-cochemical properties of econazole-loaded poly(butyl cyanoacrylate) colloidal nanoparticles. Colloids Surf A Physicochem Eng Asp. 2012; 413:260–265.
22. Kreuter J, Alyautdin RN, Kharkevich DA, Ivanov AA. Passage of pep-tides through the blood–brain barrier with colloidal polymer particles (nanoparticles). Brain Res. 1995;674(1):171–174.
23. Friese A, Seiller E, Quack G, Lorenz B, Kreuter J. Increase of the duration of the anticonvulsive activity of a novel NMDA receptor antagonist using poly(butylcyanoacrylate) nanoparticles as a parenteral controlled release system. Eur J Pharm Biopharm. 2000;49(2):103–109.
24. Page-Clisson ME, Pinto-Alphandary H, Ourevitch M, Andremont A, Couvreur P. Development of ciprofloxacin-loaded nanopar-ticles: physicochemical study of the drug carrier. J Control Release. 1998;56(1–3):23–32.
25. Miyazaki S, Takahashi A, Kubo W, Bachynsky J, Loebenberg R. Poly n-butylcyanoacrylate (PNBCA) nanocapsules as a carrier for NSAIDs: in vitro release and in vivo skin penetration. J Pharm Pharm Sci. 2003; 6(2):238–245.
26. Kuo YC, Chen HH. Effect of nanoparticulate polybutylcyanoacrylate and methylmethacrylate–sulfopropylmethacrylate on the permeability of zidovudine and lamivudine across thein vitroblood–brain barrier. Int J Pharm. 2006;327(1–2):160–169.
27. Wohlfart S, Khalansky AS, Gelperina S, Begley D, Kreuter J. Kinetics of transport of doxorubicin bound to nanoparticles across the blood– brain barrier. J Control Release. 2011;154:103–107.
28. Gao K, Jiang X. Infuence of particle size on transport of methotrexate across blood–brain barrier by polysorbate 80-coated polybutylcyano-acrylate nanoparticles. Int J Pharm. 2006;310(1–2):213–219.
29. Joshi SA, Chavhan SS, Sawant KK. Rivastigmine-loaded PLGA and PBCA nanoparticles: preparation, optimization, characterization, in vitro and pharmacodynamic studies. Eur J Pharm Biopharm. 2010; 76(2):189–189.
30. Wilson B, Sampath KP, Santhi K, Kumar KPS, Paramakrishnan N, Suresh B. Targeted delivery of tacrine into the brain with polysorbate 80-coated poly(n-butylcyanoacrylate) nanoparticles. Eur Pharm Bio-pharm. 2008;70:75–84.
31. Pimple S, Manjappa AS, Ukawala M, Murthy RSR. PLGA nanoparticles loaded with etoposide and quercetin dihydrate individually: in vitro cell line study to ensure advantage of combination therapy. Cancer Nanotechnol. 2012;3:25–36.
32. Das D, Lin S. Double-coated poly(butylcyanoacrylate) nanoparticulate delivery systems of brain targeting of dalargin via oral administration. J Pharm Sci. 2005;94(6):1343–1353.
33. Bose S, Duc Y, Takhistov P, Michniak-Kohn B. Formulation optimization and topical delivery of quercetin from solid lipid based nanosys-tems. Int J Pharm. 2013;441(1–2):56–66.
34. Tian X, Lin X, Wei F, et al. Enhanced brain targeting of temozolomide in polysorbate-80 coated polybutylcyanoacrylate nanoparticles. Int J Nanomedicine. 2011;6:445–452.
35. Jain S, Jain AK, Pohekar M, Thanki K. Novel self-emulsifying formulation of quercetin for improved in vivo antioxidant potential: implications for drug-induced cardiotoxicity and nephrotoxicity. Free Radic Biol Med. 2013;65:117–130.
36. Bhandari R, Kaur IP. Pharmacokinetics, tissue distribution and relative bioavailability of isoniazid-solid lipid nanoparticles. Int J Pharm. 2013;441(1–2):202–212.
37. Reddy LH, Murthy RR. Infuence of polymerization technique and experimental variables on the particle properties and release kinetics of methotrexate from poly(butylcyanoacrylate) nanoparticles. Acta Pharm. 2004;54:103–118.
38. Behan N, Birkinshaw C. Mechanism of polymerization of butylcyano-acrylate in aqueous dispersions. Macromol Rapid Commun. 2000;21: 884–886.
39. Behan N, Birkinshaw C, Clarke N. Polyn-butyl cyanoacrylate nanopar-ticles: a mechanistic study of polymerisation and particle formation. Biomaterials. 2001;22(11):1335–1344.
40. Yordanov G, Skrobanska R, Evangelatov A. Colloidal formulations of etoposide based on poly(butyl cyanoacrylate) nanoparticles: preparation, physicochemical properties and cytotoxicity. Colloids Surf B Biointerfaces. 2013;101:215–222.
41. Huang J, Si L, Jiang L, Fan Z, Qiu J, Li G. Effect of pluronic F68 block copolymer on P-glycoprotein transport and CYP3A4 metabolism. Int J Pharm. 2008;356:351–353.
42. Duan J, Zhang Y, Han S, et al. Synthesis and in vitro/in vivo anti-cancer evaluation of curcumin-loaded chitosan/poly(butyl cyanoacrylate) nanoparticles. Int J Pharm. 2010;400(1–2):211–220.
43. Muller RH, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery-are view of the state of the art. Eur J Pharm Biopharm. 2000;50:161–177.
44. Wu T, Ye n F, Lin L, Tsai T, Lin C, Cham T. Preparation, physicochemi-cal characterization, and antioxidant effect of quercetin nanoparticles. Int J Pharm. 2008;346(1–2):160–168.
45. Souza MP, Vaz AFM, Correia MTS, Serqueira MA, Vicente AA, Carneiro-da-cunha MG. Quercetin-loaded lecithin/chitosan nano-particles for functional food applications. Food Bioprocess Technol. 2014;7(4):1149–1159.
46. Mulik R, Mahadik K, Paradkar A. Development of curcuminoids loaded poly(butyl) cyanoacrylate nanoparticles: physicochemical characterization and stability study. Eur J Pharm Sci. 2009;37(3–4):395–404.
47. Graefe EU, Wittig J, Mueller S, et al. Pharmacokinetics and bioavail-ability of quercetin glycosides in humans. J Clin Pharmacol. 2001; 41(5):492–499.
48. Manach C, Texier O, Morand C, et al. Comparison of the bioavail-ability of quercetin and catechin in rats. Free Radic Biol Med. 1999; 27(11–12):1259–1266.
49. Jain AK, Thanki K, Jain S. Co-encapsulation of tamoxifen and quer-cetin in polymeric nanoparticles: implications on oral bioavailability, antitumor efficacy, and drug-induced toxicity. Mol Pharm. 2013;10(9): 3459–3474.
50. Ghosh A, Mandal AK, Sarkar S, Panda S, Das N. Nanoencapsula-tion of quercetin enhances its dietary efficacy in combating arsenic-induced oxidative damage in liver and brain of rats. Life Sci. 2009;84: 75–80.
51. Alyautdin RN, Tezikov EB, Ramge P, Kharkevich DA, Begley DJ, Kreuter J. Significant entry of tubocurarine into the brain of rats by adsorption to polysorbate 80-coated polybutylcyanoacrylate nanoparticles: an in situ brain perfusion study. J Microencapsul. 1998;15(1):67–74.